Application of synaptic binding protein 11 as marker in preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia

By using synaptic binding protein 11 as a marker and dopamine D2 receptor as therapeutic targets, the difficulties in diagnosis and treatment of schizophrenia are solved, and effective evaluation and treatment of negative symptoms and cognitive impairment are achieved.

CN119662803APending Publication Date: 2025-03-21SUZHOU JIELESI BIOTECHNOLOGY CO LTD
0 Cites 2 Cited by

Patent Information

Application Number
CN202411783693.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-05
Publication Date
2025-03-21

AI Technical Summary

Technical Problem

The lack of effective diagnostic markers and detection methods in the prior art, resulting in the diagnosis of schizophrenia is a huge challenge for clinicians, and existing therapeutic drugs are only effective for positive symptoms and are ineffective for negative symptoms and cognitive impairment.

Method used

Using synaptic binding protein 11 as a marker, it is used in the preparation of products for diagnosis, auxiliary diagnosis, screening and auxiliary screening of schizophrenia, and using synaptic binding protein 11 and/or dopamine D2 receptors as core targets, new methods for the treatment of schizophrenia are developed.

Benefits of technology

The reduced expression of synaptic binding protein 11 was identified as an important mechanism for the pathological process of negative schizophrenia, providing an effective single clinical diagnostic marker, and providing a key drug target for SCZ clinical treatment, improving the accuracy of diagnosis and targeted treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to application of synaptic binding protein 11 serving as a marker to preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia and application of the synaptic binding protein 11 and / or a dopamine D2 receptor serving as a core target to treatment of schizophrenia. The application of the synaptic binding protein 11 or the transcriptional product mRNA or the mRNA fragment of the synaptic binding protein 11 as the marker in any one of the following items: 1) application in preparation of products for diagnosis or auxiliary diagnosis of schizophrenia of human or non-human mammals; 2) application in preparation of products for screening or auxiliary screening of schizophrenia of human or non-human mammals; 3) application in diagnosis or auxiliary diagnosis of schizophrenia of human or non-human mammals to be detected; and 4) application in screening or auxiliary screening of schizophrenia of human or non-human mammals to be detected. Meanwhile, the invention also provides application of treating three symptoms of schizophrenia through a brain region specific targeting dopamine D2 receptor. Researches find that synaptic binding protein 11 or a transcription product mRNA or mRNA fragment thereof can be used as a brand new functional schizophrenia diagnosis marker, and a chemical molecule or gene therapy drug targeting synaptic binding protein 11 or a dopamine D2 receptor can effectively improve three symptoms of schizophrenia.
Need to check novelty before this filing date? Find Prior Art